Rational development of a novel TFPI-like inhibitor from Amblyomma cajennense tick

References

• Akagi EM, Júnior PL, Simons SM, et al. (2012). Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma “in vitro". Biomed Pharmacother 66:64–9
   PubMedGoogle Scholar
• Almond JB, Cohen GM. (2002). The proteasome: a novel target for cancer chemotherapy. Leukemia 16:433–43
   PubMed Web of Science ®Google Scholar
• Amirkhosravi A, Meyer T, Amaya M, et al. (2007). The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 33:643–52
   PubMed Web of Science ®Google Scholar
• Batista IF, Chudzinski-Tavassi AM, Faria F, et al. (2008). Expressed sequence tags (ESTs) from the salivary glands of the tick Amblyomma cajennense (Acari: Ixodidae). Toxicon 51:823–34
   Google Scholar
• Batista IF, Ramos OH, Ventura JS, et al. (2010). A new Factor Xa inhibitor from Amblyomma cajennense with a unique domain composition. Arch Biochem Biophys 493:151–6
   PubMed Web of Science ®Google Scholar
• Baugh RJ, Dickinson CD, Ruf W, Krishnaswamy S. (2000). Exosite interactions determine the affinity of FX for the extrinsic Xase complex. J Biol Chem 275:28826–33
   PubMedGoogle Scholar
• Bowman AS, Coons LB, Needham GR, Sauer JR. (1997). Tick saliva: recent advances and implications for vector competence. Med Vet Entomol 11:277–85
   PubMed Web of Science ®Google Scholar
• Burgering MJM, Orbons LPM, van der Doelen A, et al. (1997). The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa. J Mol Biol 269:395–407
   PubMed Web of Science ®Google Scholar
• Carneiro-Lobo TC, Konig S, Machado DE, et al. (2009). Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J Thromb Haemost 7:1855–64
   PubMed Web of Science ®Google Scholar
• Chudzinski-Tavassi AM, De-Sá-Junior P, Simons SM, et al. (2010). Induction of cell death and tumor mass regression in a murine melanoma model by a new Kunitz-type serine protease inhibitor. Toxicon 56:1145–54
   Google Scholar
• Clamp M, Cuff J, Searle SM, Barton GJ. (2004). The Jalview Java alignment editor. Bioinformatics 20:426–7
   PubMed Web of Science ®Google Scholar
• Coux O, Nothwang HG, Silva Pereira I, et al. (1994). Phylogenic relationships of the amino acid sequences of prosome (proteasome, MCP) subunits. Mol Gen Genet 245:769–80
   Google Scholar
• Dickinson CD, Kelly CR, Ruf W. (1996). Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc Natl Acad Sci USA 93:14379–84
   PubMed Web of Science ®Google Scholar
• Francischetti IMB, Valenzuela JG, Andersen JF, et al. (2002). Ixolaris, A novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibitor of factor VII/Tissue factor complex. Blood 99:3602–12
   PubMed Web of Science ®Google Scholar
• Francischetti IMB, Mather TN, Ribeiro JM. (2004). Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis. Thromb Haemost 91:886–98
   PubMed Web of Science ®Google Scholar
• Fribley A, Zeng Q, Wang CY. (2004). Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:9695–704
   PubMed Web of Science ®Google Scholar
• Glickman MH, Ciechanover A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373--428
   Google Scholar
• Hembrough TA, Swartz GM, Papathanassiu A, et al. (2003). Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 63:2997–3000
   PubMed Web of Science ®Google Scholar
• Hengartner MO. (2000). The biochemistry of apoptosis. Nature 407:770–6
   PubMed Web of Science ®Google Scholar
• Larkin MA, Blackshields G, Brown NP, et al. (2007). Clustal W and Clustal X version 2.0. Bioinformatics 23:2947–8
   PubMed Web of Science ®Google Scholar
• Goujon M, McWilliam H, Li W, et al. (2010). A new bioinformatics analysis tools framework at EMBL–EBI. Nucleic Acids Res 38:W695–9
   PubMed Web of Science ®Google Scholar
• Kirchhofer D, Lipari MT, Moran P, et al. (2000). The tissue factor region that interacts with substrates factor IX and Factor X. Biochemistry 39:7380–7
   Google Scholar
• Kirchhofer D, Eigenbrot C, Lipari MT, et al. (2001). The tissue factor region that interacts with factor Xa in the activation of factor VII. Biochemistry 40:675–82
   Google Scholar
• Koh CY, Kini RM. (2009). Molecular diversity of anticoagulants from haematophagous animals. Thromb Haemost 102:437–53
   Google Scholar
• Lee AY, Vlasuk GP. (2003). Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med 254:313–21
   PubMed Web of Science ®Google Scholar
• Ludwig H, Khayat D, Giaccone G, Facon T. (2005). Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104:1794–807
   PubMed Web of Science ®Google Scholar
• Maria DA, de Souza JG, Morais KL, et al. (2013). A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production. Invest New Drugs 31:493–505
   PubMed Web of Science ®Google Scholar
• McCann CJ, Menown IB. (2008). New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implications. Vasc Health Risk Manag 4:305–13
   PubMedGoogle Scholar
• Monteiro RQ, Rezaie AR, Bae JS, et al. (2008). Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite. Protein Sci 17:146–53
   PubMed Web of Science ®Google Scholar
• Murakami MT, Rios-Steiner J, Weaver SE, et al. (2007). Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum. J Mol Biol 366:602–10
   PubMed Web of Science ®Google Scholar
• Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. (2004). The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3:59–70
   PubMed Web of Science ®Google Scholar
• Nuttall PA, Labuda M. (2004). Tick-host interactions: saliva-activated transmission. Parasitology 129:S177–89
   Google Scholar
• Schmidt AE, Chand HS, Cascio D, et al. (2005). Crystal structure of Kunitz domain 1 (KD1) of tissue factor pathway inhibitor-2 in complex with trypsin: implications for KD1 specificity of inhibition. J Biol Chem 280:27832–8
   Google Scholar
• Schroder M, Kaufman RJ. (2005). The mammalian unfolded protein response. Annu Rev Biochem 74:739–89
   PubMed Web of Science ®Google Scholar
• Ventura JS, Faria F, Batista IFC, et al. (2013). A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis. Biomed Pharmacother 67:192–6
   Google Scholar
• Zhao J, Aguilar G, Palencia S, et al. (2009). rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res 15:208–16
   PubMedGoogle Scholar